Pharmacokinetic aspects of neuroleptics and prediction of outcome
A number of characteristics of antipsychotic medications have inspired a search for early predictors of drug response. Unless a clinician has a well-documented history that a patient will respond to a particular drug or drug dose, treatment decisions will usually be made on a trial and error basis. After a decision is made to begin a trial of a particular regimen, the clinician and patient will often have to wait for weeks or even months before it is established that the treatment is successful. Moreover, if the patient fails to respond to an adequate trial of a particular drug, the clinician may be unsure if the drug was an effective one that was administered at too high or too low a dose. For these reasons, researchers have searched for pharmacokinetic indicators which can guide pharmacotherapy.
KeywordsAntipsychotic Activity Plasma Level Measurement Fluphenazine Decanoate Pharmacokinetic Aspect Dopamine Receptor Occupancy
Unable to display preview. Download preview PDF.
- Cohen BM, Waternaux C (1993) Neuroleptic plasma levels: limitations and values. In: Marder SR, Davis JM, Janicak PG (eds) Clinical use of neuroleptic plasma levels. American Psychiatric Press, Washington DC London, pp 1–15.Google Scholar
- Jorgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. In: Bridges JW, Chasseaud LF (eds) Progress in drug metabolism. Taylor and Francis, London Philadelphia, pp 111–174.Google Scholar
- Levinson DF, Simpson GM, Lo ES, Cooper TB (1993) Fluphenazine plasma levels, dosage and acute treatment response In: Marder SR, Davis JM, Janicak PG (eds) Clinical use of neuroleptic plasma levels. American Psychiatric Press, Washington DC London, pp 45–61.Google Scholar
- Midha KK, Hawes EM, Hubbard JW, Korchinski ED, McKay G (1989) Intersubject variation in the pharmacokinetics of chlorpromazine in healthy men. J Clin Psychopharmacol 9:48.Google Scholar
- Van Putten T, Aravagiri M, Marder SR, Wirshing WC, Mintz J, Chabert N (1991a) Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients. Psy-chopharmacol Bull 27:91–96.Google Scholar